Your browser doesn't support javascript.
loading
The decreased achievement of therapeutic goal in lipid lowering therapy in obese and diabetic patients in Poland.
Holecki, Michal; Handzlik-Orlik, Gabriela; Almgren-Rachtan, Agnieszka; Dulawa, Jan; Chudek, Jerzy.
Afiliação
  • Holecki M; Department of Internal Medicine and Metabolic Diseases, School of Health Science in Katowice, Medical University of Silesia, Katowice, Poland.
  • Handzlik-Orlik G; Department of Internal Medicine and Metabolic Diseases, School of Health Science in Katowice, Medical University of Silesia, Katowice, Poland. Electronic address: gabriela.handzlik@hotmail.com.
  • Almgren-Rachtan A; Department of Pharmacovigilance, Europharma Rachtan Co. Ltd., Katowice, Poland.
  • Dulawa J; Department of Internal Medicine and Metabolic Diseases, School of Health Science in Katowice, Medical University of Silesia, Katowice, Poland.
  • Chudek J; Pathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland.
Pharmacol Rep ; 69(1): 6-12, 2017 Feb.
Article em En | MEDLINE | ID: mdl-27755993
BACKGROUND: Statins are used to reduce a cardiovascular risk. However, the effectiveness of the therapy in many cases remains unsatisfactory. Therefore, the aim of this study was to evaluate the influence of obesity and diabetes on the achievement of therapeutic goal in lipid-lowering therapy in patients with a various cardiovascular risk in the daily clinical practice. METHODS: This study was conducted on the basis of questionnaires obtained from 7018 patients (41.4% obese, 65.9% viscerally obese and 25.3% diabetics) treated with statins for at least three months. The effectiveness of the treatment was assessed in a subgroup of 3218 patients with a full lipid profile. RESULTS: The LDL-cholesterol target, adjusted for cardiovascular risk, was obtained by 8.1% of patients, less frequently by those with a very high risk of a cardiovascular disease (3.7%), obesity (5.5%), visceral obesity (5.5%) and the type 2 diabetes (5.3%). The obese patients with type 2 diabetes were the least likely to reach the target (3.0%). Male gender, age, the body mass index (BMI)≥28kg/m2, visceral obesity, type 2 diabetes, and a low/moderate statin dose prescription were independent factors decreasing the chance of reaching the low-density lipoprotein (LDL) cholesterol target. CONCLUSIONS: 1. The prescribed statin doses do not fully explain the lower frequency of achieving the recommended target in a lipid-lowering therapy in the obese patients and the diabetics. 2. In the daily clinical practice the doses of statins are frequently insufficient and not adjusted for a cardiovascular risk.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Logro / Inibidores de Hidroximetilglutaril-CoA Redutases / Diabetes Mellitus Tipo 2 / Objetivos / Hipolipemiantes / Obesidade Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Logro / Inibidores de Hidroximetilglutaril-CoA Redutases / Diabetes Mellitus Tipo 2 / Objetivos / Hipolipemiantes / Obesidade Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article